Statins Enhances Anti-Androgen Abiraterone Acetate Therapeutic Efficacy on Castration-Resistant Prostate Cancer Cells

Treatment options for castration-resistant (CR) prostate cancer (PCa) are limited. Because a significant subset of CR PCa tumours can produce androgens for intracrine androgen receptor (AR) activation, blocking androgen biosynthesis may be a viable therapy strategy for these individuals. Simvastatin,

Read More